C19
Drug-Resistant Hepatocellular Carcinoma
Pre-clinicalUS & PCT Patent Pending
Key Facts
Indication
Drug-Resistant Hepatocellular Carcinoma
Phase
Pre-clinical
Status
US & PCT Patent Pending
Company
About CKP Therapeutics
CKP Therapeutics is dedicated to lengthening life expectancy and improving quality of life for patients with refractory advanced cancers. The company employs a unique drug discovery platform to identify compounds that directly target cancer stem cells (CSCs), a key driver of recurrence and metastasis, by inhibiting the SERCA protein. Its strategy involves developing both combination therapies with standard treatments and stand-alone therapeutics, with an initial focus on solid tumors representing 90% of adult cancer cases. The team comprises experienced business, legal, and medical experts driving the translation of frontier cancer research into clinical solutions.
View full company profileTherapeutic Areas
Other Drug-Resistant Hepatocellular Carcinoma Drugs
| Drug | Company | Phase |
|---|---|---|
| C23 | CKP Therapeutics | Pre-clinical |